{
  "api_version": "1",
  "request": {
    "url": "https://clinicaltrialsfind.com/api/v1/search.json?sponsor=OPKO+Health%2C+Inc.",
    "query": {
      "sponsor": "OPKO Health, Inc."
    },
    "page_size": 10
  },
  "pagination": {
    "page": 1,
    "page_size": 10,
    "total_count": 39,
    "total_pages": 4,
    "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?sponsor=OPKO+Health%2C+Inc.&page=2&page_size=10",
    "previous_page_url": null
  },
  "source": "remote",
  "last_synced_at": "2026-10-05T22:27:04.327Z",
  "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.",
  "notes": [
    "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.",
    "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.",
    "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees."
  ],
  "trials": [
    {
      "nct_id": "NCT00792857",
      "title": "Comparison of I.V. CTAP201 and Doxercalciferol (Hectorol) in Subjects With Chronic Kidney Disease (CKD) and Secondary Hyperparathyroidism (SHPT)",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Chronic Kidney Disease",
        "Secondary Hyperparathyroidism",
        "Chronic Renal Insufficiency",
        "Chronic Renal Failure"
      ],
      "interventions": [
        {
          "name": "CTAP201 Injection",
          "type": "DRUG"
        },
        {
          "name": "Doxercalciferol",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "OPKO IP Holdings II, Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "80 Years",
        "sex": "ALL",
        "summary": "18 Years to 80 Years"
      },
      "enrollment_count": 24,
      "start_date": "2008-11",
      "completion_date": "2009-10",
      "has_results": false,
      "last_update_posted_date": "2014-09-29",
      "last_synced_at": "2026-10-05T22:27:04.327Z",
      "location_count": 6,
      "location_summary": "Peoria, Arizona • Springfield, Massachusetts • Cincinnati, Ohio + 3 more",
      "locations": [
        {
          "city": "Peoria",
          "state": "Arizona"
        },
        {
          "city": "Springfield",
          "state": "Massachusetts"
        },
        {
          "city": "Cincinnati",
          "state": "Ohio"
        },
        {
          "city": "Allentown",
          "state": "Pennsylvania"
        },
        {
          "city": "Nashville",
          "state": "Tennessee"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00792857"
    },
    {
      "nct_id": "NCT03602261",
      "title": "Safety, Efficacy, PK and PD of CTAP101 (Calcifediol) ER Capsules for SHPT in HD Patients VDI",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Secondary Hyperparathyroidism Due to Renal Causes",
        "Chronic Kidney Diseases",
        "Vitamin D Deficiency",
        "Stage 5 Chronic Kidney Disease"
      ],
      "interventions": [
        {
          "name": "Calcifediol Oral Capsule",
          "type": "DRUG"
        },
        {
          "name": "Placebo oral capsule",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "OPKO Health, Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 44,
      "start_date": "2018-07-09",
      "completion_date": "2021-02-24",
      "has_results": true,
      "last_update_posted_date": "2026-04-03",
      "last_synced_at": "2026-10-05T22:27:04.327Z",
      "location_count": 18,
      "location_summary": "Peoria, Arizona • Phoenix, Arizona • Cypress, California + 13 more",
      "locations": [
        {
          "city": "Peoria",
          "state": "Arizona"
        },
        {
          "city": "Phoenix",
          "state": "Arizona"
        },
        {
          "city": "Phoenix",
          "state": "Arizona"
        },
        {
          "city": "Phoenix",
          "state": "Arizona"
        },
        {
          "city": "Cypress",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03602261"
    },
    {
      "nct_id": "NCT05543928",
      "title": "Phase 3 Safety and Efficacy Study of CTAP101 Extended-release Capsules in Children With Secondary Hyperparathyroidism",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Chronic Kidney Disease stage3",
        "Chronic Kidney Disease stage4",
        "Vitamin d Deficiency",
        "Secondary Hyperparathyroidism"
      ],
      "interventions": [
        {
          "name": "CTAP101",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "OPKO Health, Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "8 Years",
        "maximum_age": "17 Years",
        "sex": "ALL",
        "summary": "8 Years to 17 Years"
      },
      "enrollment_count": 2,
      "start_date": "2023-01-31",
      "completion_date": "2024-06-19",
      "has_results": true,
      "last_update_posted_date": "2025-07-25",
      "last_synced_at": "2026-10-05T22:27:04.327Z",
      "location_count": 2,
      "location_summary": "Columbus, Ohio • Greenville, South Carolina",
      "locations": [
        {
          "city": "Columbus",
          "state": "Ohio"
        },
        {
          "city": "Greenville",
          "state": "South Carolina"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT05543928"
    },
    {
      "nct_id": "NCT00743002",
      "title": "A Trial of TT223 in Patients With Type 2 Diabetes Who Are Taking Metformin and/or Thiazolidinedione",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Diabetes Mellitus, Type 2"
      ],
      "interventions": [
        {
          "name": "TT223 with Metformin and/or TZD",
          "type": "DRUG"
        },
        {
          "name": "Placebo with Metformin and/or TZD",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "OPKO Health, Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "75 Years",
        "sex": "ALL",
        "summary": "18 Years to 75 Years"
      },
      "enrollment_count": 87,
      "start_date": "2008-08",
      "completion_date": "2009-12",
      "has_results": false,
      "last_update_posted_date": "2013-06-21",
      "last_synced_at": "2026-10-05T22:27:04.327Z",
      "location_count": 20,
      "location_summary": "Artesia, California • Los Angeles, California • Santa Ana, California + 17 more",
      "locations": [
        {
          "city": "Artesia",
          "state": "California"
        },
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "Santa Ana",
          "state": "California"
        },
        {
          "city": "Torrence",
          "state": "California"
        },
        {
          "city": "Walnut Creek",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00743002"
    },
    {
      "nct_id": "NCT01357421",
      "title": "Effects of TT301 on Cytokine Levels Post Endotoxin Challenge",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Traumatic Brain Injury"
      ],
      "interventions": [
        {
          "name": "TT301",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "OPKO Health, Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "40 Years",
        "sex": "MALE",
        "summary": "18 Years to 40 Years · Male only"
      },
      "enrollment_count": 18,
      "start_date": "2011-05",
      "completion_date": "2011-06",
      "has_results": false,
      "last_update_posted_date": "2013-06-06",
      "last_synced_at": "2026-10-05T22:27:04.327Z",
      "location_count": 1,
      "location_summary": "Durham, North Carolina",
      "locations": [
        {
          "city": "Durham",
          "state": "North Carolina"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01357421"
    },
    {
      "nct_id": "NCT01674010",
      "title": "Safety and Efficacy Study of ELND005 as an Adjunctive Maintenance Treatment in Bipolar I Disorder",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Bipolar 1 Disorder"
      ],
      "interventions": [
        {
          "name": "ELND005",
          "type": "DRUG"
        },
        {
          "name": "Lamotrigine",
          "type": "DRUG"
        },
        {
          "name": "Valproic acid",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "OPKO Health, Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "65 Years",
        "sex": "ALL",
        "summary": "18 Years to 65 Years"
      },
      "enrollment_count": 309,
      "start_date": "2012-08",
      "completion_date": "2014-06",
      "has_results": true,
      "last_update_posted_date": "2019-10-21",
      "last_synced_at": "2026-10-05T22:27:04.327Z",
      "location_count": 41,
      "location_summary": "Birmingham, Alabama • Glendale, Arizona • Phoenix, Arizona + 36 more",
      "locations": [
        {
          "city": "Birmingham",
          "state": "Alabama"
        },
        {
          "city": "Glendale",
          "state": "Arizona"
        },
        {
          "city": "Phoenix",
          "state": "Arizona"
        },
        {
          "city": "Little Rock",
          "state": "Arkansas"
        },
        {
          "city": "Little Rock",
          "state": "Arkansas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01674010"
    },
    {
      "nct_id": "NCT00934050",
      "title": "ELND005 Long-Term Follow-up Study in Subjects With Alzheimer's Disease",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Alzheimer's Disease"
      ],
      "interventions": [
        {
          "name": "ELND005 (scyllo-inositol)",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "OPKO Health, Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": null,
        "maximum_age": null,
        "sex": "ALL",
        "summary": "Not listed"
      },
      "enrollment_count": 103,
      "start_date": "2009-06",
      "completion_date": "2011-06",
      "has_results": true,
      "last_update_posted_date": "2019-10-21",
      "last_synced_at": "2026-10-05T22:27:04.327Z",
      "location_count": 30,
      "location_summary": "Phoenix, Arizona • Sun City, Arizona • Tucson, Arizona + 27 more",
      "locations": [
        {
          "city": "Phoenix",
          "state": "Arizona"
        },
        {
          "city": "Sun City",
          "state": "Arizona"
        },
        {
          "city": "Tucson",
          "state": "Arizona"
        },
        {
          "city": "Fresno",
          "state": "California"
        },
        {
          "city": "Garden Grove",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00934050"
    },
    {
      "nct_id": "NCT03588884",
      "title": "Repeated-dose Safety, Efficacy, Pharmacokinetic and Pharmacodynamic of CTAP101, Immediate-release Calcifediol, High-dose Cholecalciferol, and Paricalcitol Plus Low-dose Cholecalciferol in Patients With Secondary Hyperparathyroidism, Chronic Kidney Disease 3-4 and Vitamin D Insufficiency",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE4"
      ],
      "conditions": [
        "Secondary Hyperparathyroidism Due to Renal Causes",
        "Vitamin D Insufficiency",
        "CKD Stage 3",
        "CKD Stage 4"
      ],
      "interventions": [
        {
          "name": "Calcifediol Oral Capsule",
          "type": "DRUG"
        },
        {
          "name": "Calcifediol Oral Product",
          "type": "DRUG"
        },
        {
          "name": "Cholecalciferol",
          "type": "DRUG"
        },
        {
          "name": "Paricalcitol Oral Capsule",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "OPKO Health, Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 69,
      "start_date": "2018-06-08",
      "completion_date": "2020-04-24",
      "has_results": true,
      "last_update_posted_date": "2022-12-09",
      "last_synced_at": "2026-10-05T22:27:04.327Z",
      "location_count": 3,
      "location_summary": "Garden Grove, California • Chicago, Illinois • West Bend, Wisconsin",
      "locations": [
        {
          "city": "Garden Grove",
          "state": "California"
        },
        {
          "city": "Chicago",
          "state": "Illinois"
        },
        {
          "city": "West Bend",
          "state": "Wisconsin"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03588884"
    },
    {
      "nct_id": "NCT03660800",
      "title": "Pharmacokinetics and Safety Study of CTAP101 Capsules in Japanese and Non-Japanese Healthy Subjects and Non-Japanese Healthy Subjects",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Vitamin D Insufficiency",
        "Secondary Hyperparathyroidism"
      ],
      "interventions": [
        {
          "name": "CTAP101 Capsules",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "OPKO Health, Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "55 Years",
        "sex": "ALL",
        "summary": "18 Years to 55 Years"
      },
      "enrollment_count": 67,
      "start_date": "2018-08-20",
      "completion_date": "2019-01-22",
      "has_results": false,
      "last_update_posted_date": "2019-09-30",
      "last_synced_at": "2026-10-05T22:27:04.327Z",
      "location_count": 1,
      "location_summary": "Cypress, California",
      "locations": [
        {
          "city": "Cypress",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03660800"
    },
    {
      "nct_id": "NCT02274623",
      "title": "Effect of CTAP101 Capsules on Ca/iPTH in Advanced Breast/Prostate Cancer Patients Treated With Denosumab/Zoledronic Acid",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Breast Cancer",
        "Prostate Cancer",
        "Bone Neoplasms",
        "Hypocalcemia",
        "Hyperparathyroidism, Secondary"
      ],
      "interventions": [
        {
          "name": "CTAP101 Capsules",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "OPKO Health, Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 33,
      "start_date": "2014-12",
      "completion_date": "2017-03-17",
      "has_results": false,
      "last_update_posted_date": "2019-09-27",
      "last_synced_at": "2026-10-05T22:27:04.327Z",
      "location_count": 6,
      "location_summary": "Long Beach, California • Miami, Florida • Evergreen Park, Illinois + 3 more",
      "locations": [
        {
          "city": "Long Beach",
          "state": "California"
        },
        {
          "city": "Miami",
          "state": "Florida"
        },
        {
          "city": "Evergreen Park",
          "state": "Illinois"
        },
        {
          "city": "Buffalo",
          "state": "New York"
        },
        {
          "city": "Cincinnati",
          "state": "Ohio"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02274623"
    }
  ]
}